|
Waist-Hip Ratio
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Uranostaphyloschisis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We provide strong genetic and biochemical evidence that hydrocephaly and white spotting in B3glct mutants resulted from loss of ADAMTS20, eye abnormalities from partial reduction of ADAMTS9, and cleft palate from loss of ADAMTS20 and partially reduced ADAMTS9 function.
|
31600785 |
2019 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Ectopic expression of ADAMTS9 in tumor cells induced significant growth suppression, cell cycle arrest at the G0/G1 phase, enhanced apoptosis and reduced cell migration and invasion.
|
29193730 |
2018 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
We proposed to find out the role of miR-338-5p played in cell proliferation and invasion of rheumatoid arthritis synovial fibroblasts (RASFs) by regulating ADAMTS-9.
|
28850027 |
2018 |
|
Tumor Angiogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Heterotopic B.16-F10 melanomas elicited greater vascular induction in ADAMTS9+/- mice than in wild-type littermates, suggesting a potential inhibitory role in tumor angiogenesis.
|
20093484 |
2010 |
|
Stomach Neoplasms
|
0.010 |
PosttranslationalModification
|
group |
BEFREE |
Moreover, promoter methylation of ADAMTS9 was detected in 29.2% (21/72) of primary gastric tumors.
|
22907434 |
2013 |
|
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Methylation of ADAMTS9 is an independent prognostic factor of gastric cancer.
|
22907434 |
2013 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our results indicate that ADAMTS9 contributes an important function in the tumor microenvironment that acts to inhibit angiogenesis and tumor growth in both ESCC and NPC.
|
20551050 |
2010 |
|
SMITH-MCCORT DYSPLASIA 1
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, pericellular versican proteolysis by ADAMTS9 balances pro- and anti-adhesive forces to maintain an SMC phenotype, providing a concrete example of the dynamic reciprocity of cells and their ECM.
|
29642006 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
0.020 |
Biomarker
|
disease |
BEFREE |
Characterization of a novel epigenetically-silenced, growth-suppressive gene, ADAMTS9, and its association with lymph node metastases in nasopharyngeal carcinoma.
|
18449890 |
2008 |
|
Secondary malignant neoplasm of lymph node
|
0.020 |
Biomarker
|
disease |
BEFREE |
The ADAMTS9 gene (ADAM metallopeptidase with thrombospondin type 1 motif, 9); has been characterized as a novel tumor suppressor gene in and epigenetically silenced in association with lymph node metastases in nasopharyngeal carcinoma.
|
19963134 |
2010 |
|
Rheumatoid Arthritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MiR-338-5p was significantly downregulated in rheumatoid arthritis (RA) tissues while ADAMTS-9 was obviously overexpressed (p<0.001).
|
28850027 |
2018 |
|
Prostatic Neoplasms
|
0.010 |
Biomarker
|
group |
LHGDN |
The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican.
|
15599946 |
2005 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
However, the functional impact of ADAMTS9 on cancer development has not been explored.
|
20551050 |
2010 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
ADAMTS9 was reported to be a novel tumor suppressor gene and is downregulated in various types of human cancer due to hypermethylation of promoter CpG islands.
|
23358566 |
2013 |
|
Primary malignant neoplasm
|
0.030 |
PosttranslationalModification
|
group |
BEFREE |
Using genome-wide promoter methylation analysis, we identified a disintegrin-like and metalloprotease with thrombospondin type 1 motif 9 (ADAMTS9) is methylated in cancer.
|
22907434 |
2013 |
|
Polycystic Ovary Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Lower expression levels of ADAMTS-1 and ADAMTS-9 in PCOS patients were strongly correlated with diminished oocyte maturation.
|
30446843 |
2019 |
|
Osteoarthritis, Knee
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Relationship between cytosine-adenine repeat polymorphism of ADAMTS9 gene and clinical and radiologic severity of knee osteoarthritis.
|
27230574 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, the data reveal that miR-190b inhibition suppressed lipid accumulation and improved insulin sensitivity by targeting IGF-1 and ADAMTS9, suggesting that miR-190b inhibition may be a therapeutic strategy against NAFLD.
|
29575055 |
2018 |
|
Nephronophthisis, familial juvenile
|
0.300 |
GermlineCausalMutation
|
disease |
ORPHANET |
Mutations of ADAMTS9 Cause Nephronophthisis-Related Ciliopathy.
|
30609407 |
2019 |
|
Nephronophthisis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Mutations of ADAMTS9 Cause Nephronophthisis-Related Ciliopathy.
|
30609407 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, when congenic with the C57Bl/6 strain, 80% of ADAMTS9+/- mice developed spontaneous corneal neovascularization. beta-Galactosidase staining enabled by a lacZ cassette targeted to the ADAMTS9 locus showed that capillary endothelial cells (ECs) in embryonic and adult tissues and in capillaries growing into heterotopic tumors expressed ADAMTS9.
|
20093484 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adaptive sequence convergence of the tumor suppressor ADAMTS9 between small-bodied mammals displaying exceptional longevity.
|
28244876 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, this study identifies and provides functional evidence for a CR associated with tumor suppression on 3p14.2 and provides the first evidence that ADAMTS9, mapping to this region, may contribute to esophageal cancer development.
|
16799631 |
2007 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The combined microarray technologies suggested novel candidate oncogenes, amplification of GPR160 and SKIL at 3q26.2-q26.32, and deletion of tumor suppressor genes ADAMTS9 and LRIG1 at 3p12.3-p14.2.
|
19815638 |
2009 |